Introduction: Globally, Acute Lymphoblastic Leukemia (ALL), represents more than 30% of all types of cancers in children aged between 0 and 9 years. In Peru, it has not been evaluated whether exclusive breastfee ding (EB) is a protective factor for ALL.

Objective: To identify the protective and risk factors associa ted with acute lymphoblastic leukemia in children aged between 0 and 13 years in a national hospital in Lima, Peru.

Patients And Method: Observational, analytical study, case-control design. 112 cases diagnosed with ALL and 229 controls were evaluated. The data were collected by interviews with the mothers of both groups. The magnitude of the association between ALL and EB was estimated using the odds ratio (OR) and multivariate logistic regression in Stata v 12.

Results: 50.9% (57/112) of the cases and 51.5% (118/229) of the controls were male. The mean age of the cases was 6.7 ± 3.2 years and of the controls 5.7 ± 3.5 years. The mean age of the mothers of the cases was 35.9 ± 6.5 and of the controls was 34.1 ± 7.1 years. EB reduces the risk of ALL by 44% compared with those who did not receive it, OR 0.56, p = 0.017, 95% CI (0.35-0.90). Complete secondary education reduces the risk of ALL by 62%, OR 0.38 CI 95% (0.15-0.61).

Conclusions: Exclusive breastfeeding and the mother's complete secondary education are protective factors for the development of ALL in children and adolescents.

Download full-text PDF

Source
http://dx.doi.org/10.32641/andespediatr.v92i1.2617DOI Listing

Publication Analysis

Top Keywords

acute lymphoblastic
12
lymphoblastic leukemia
12
exclusive breastfeeding
8
protective factor
8
children aged
8
aged years
8
reduces risk
8
complete secondary
8
secondary education
8
years
5

Similar Publications

The significance of endogenous immune surveillance in acute lymphoblastic leukemia (ALL) remains controversial. Using clinical B-ALL samples and a novel mouse model, we show that neoantigen-specific CD4+ T cells are induced to adopt type-1 regulatory (Tr1) function in the leukemia microenvironment. Tr1s then inhibit cytotoxic CD8+ T cells, preventing effective leukemia clearance.

View Article and Find Full Text PDF

Umbilical cord blood (UCB) represents a valuable graft source in the absence of a human leukocyte antigen (HLA)-matched donor for hematopoietic cell transplantation (HCT). Donor-specific anti-HLA antibodies (DSAs), targeting grafts with mismatched HLA antigens, pose a significant obstacle by increasing the risk of primary graft failure, delayed engraftment, and decreased survival. Existing literature on HLA desensitization has primarily focused on haploidentical transplants, and there is a lack of experience regarding the optimal strategy in UCB transplantation.

View Article and Find Full Text PDF

Utility of Daratumumab as Bridging Therapy in De Novo T-Cell Acute Lymphoblastic Lymphoma.

Pediatr Blood Cancer

January 2025

Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation, Perth Children's Hospital, Perth, Western Australia, Australia.

View Article and Find Full Text PDF

Background: Multiple factors have been described to influence the risk of acute or chronic graft-versus-host disease (aGVHD or cGVHD) after allogeneic hematopoietic cell transplantation (HCT), including underlying chronic myeloid leukemia (CML) and high-dose total body irradiation (TBI). However, the impact of the underlying disease or low-dose TBI on the risk of GVHD in the modern era has not been determined.

Objective: To determine risk factors for GVHD in the modern era in the setting of antithymocyte globulin (ATG)-based GVHD prophylaxis.

View Article and Find Full Text PDF

INTRODUCTION ETV6::JAK2 is a fusion known to drive Acute Lymphoblastic Leukaemia (ALL) in the presence of other genomic lesions which define the JAK/STAT class of Philadelphia-like Acute Lymphoblastic Leukaemia (Ph-like ALL). Ph-like ALL comprises approximately 15% of ALL. Patients with mutations or gene fusions signaling through the JAK/STAT pathway have particularly poor prognosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!